No Data
No Data
Precision BioSciences to Participate in Upcoming June Investor Conferences
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene
Buy Rating on Precision BioSciences: Leading the Way in Gene Editing for Chronic Hepatitis B
Buy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market Potential
Express News | Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Express News | HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
Precision BioSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 395.87% HC Wainwright & Co. → $60 Reiterates Buy → Buy 04/30/2024 57.02% Guggenheim → $19 Initi
No Data